OFIX
Orthofix Medical Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- S Mar 4 to Mar 5 2 days of insider sells: $360.7K by 7 insiders, avg $12.74
- B Mar 9 to Mar 10 2 days of insider buys: $62.3K by 1 insider, avg $12.46
- B May 5 to May 7 3 days of insider buys: $2.3M by 2 insiders, avg $12.08
- R May 21 Orthofix disclosed that CMS updated billing requirements for non-inv…
- S Aug 14 to Aug 18 3 days of insider sells: $415.8K by 2 insiders, avg $10.19
- B Sep 18 to Sep 21 2 days of insider buys: $2.7M by 1 insider, avg $8.81
- S Sep 18 to Sep 21 2 days of insider sells: $2.7M by 1 insider, avg $8.81
- S Oct 1 1 insider sell $1.4K at $9.44
Signal stack
Where each data set points today.
- InsidersMIXED
4 insiders bought $5.1M at an average $10.08. 8 insiders sold $6.2M.
- InstitutionsBULLISH
Q2 2026: 17 added (0 new), 8 trimmed or exited.
- AnalystsBULLISH
8 of 11 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate $0.080 → $0.110 over 90 days. 1 up, 0 down in 30 days.
- TrendUPTREND
3% above its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| JACOBS LEVY EQUITY MANAGEMENT, INC | ADD | $4.4M |
| GOLDMAN SACHS GROUP INC | ADD | $4.1M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | $3.1M |
| MORGAN STANLEY | ADD | $2.7M |
| BANK OF AMERICA CORP /DE/ | ADD | $2.7M |
| FMR LLC | DOUBLED | $2.4M |
| UBS Group AG | ADD | $1.7M |
| GABELLI FUNDS LLC | TRIM | $999.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analystsPrice is below the lowest target. Median implies +34%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Aug 10, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Jul 6, 2026 | Barrington Research MAINTAIN | Outperform |
| May 22, 2026 | Canaccord Genuity MAINTAIN | Buy |
| May 22, 2026 | Barrington Research MAINTAIN | Outperform |
| May 22, 2026 | Stifel MAINTAIN | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 1, 2026 | Fisher Patrick President, Global Limb Recon | SELL | $1.4K |
| Sep 21, 2026 | Juniper Investment Company, LLC 10%+ Owner | SELL | $1.7M |
| Sep 21, 2026 | Juniper Investment Company, LLC 10%+ Owner | BUY | $1.7M |
| Sep 18, 2026 | Juniper Investment Company, LLC 10%+ Owner | SELL | $1.0M |
| Sep 18, 2026 | Juniper Investment Company, LLC 10%+ Owner | BUY | $1.0M |
| Sep 1, 2026 | Fisher Patrick President, Global Limb Recon | SELL | $1.4K |
| Aug 18, 2026 | Fisher Patrick President, Global Limb Recon | SELL | $13.1K |
| Aug 17, 2026 | Juniper Investment Company, LLC 10%+ Owner | SELL | $200.3K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.11 | $0.11–$0.11 | +0.0% | $210.5M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | $0.41 | $0.41–$0.41 | +0.0% | $851.2M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026SecBot reports
11 filings · 3 bullish · 2 bearish · 6 neutral- NEUTRAL INSIDER-BUYSep 23, 2026
A 10% owner, Juniper Investment Company, LLC, made a $2.73M open-market purchase of OFIX shares…
The simultaneous buy and sell by the same 10% owner at nearly identical prices and volumes suggests a non-directional restructuring (e.g., tax planning, portfolio rebalancing, or derivative unwind)…
- NEUTRAL CLUSTERAug 20, 2026
Two insiders at Orthofix Medical sold a total of $213K in stock over a 7-day window, with the…
No immediate action warranted; monitor for any C-suite sales or a material increase in selling volume above 0.1% of market cap.
- BULLISH 8-KAug 5, 2026
Orthofix reported Q2 2026 revenue of $210.9M (+5% pro forma constant currency YoY) and GAAP EPS of…
The raised guidance signals improving operational momentum and visibility. Watch for continued execution in U.S. spine and biologics recovery; the Medicare reimbursement restoration for bone growth…
- BULLISH 8-KJul 2, 2026
Orthofix disclosed that CMS withdrew its earlier changes to Medicare billing for non-invasive bone…
This reversal removes a key uncertainty for Orthofix's bone growth stimulator revenue. Monitor upcoming quarterly filings for quantification of the benefit and any changes in payer behavior. The…
All OFIX filing & press-release reports (11)
- INSIDER-BUY reportSep 23, 2026
- CLUSTER reportAug 20, 2026
- 8-K reportAug 5, 2026
- 8-K reportJul 2, 2026
- 8-K reportMay 21, 2026
- 8-K reportMay 5, 2026
- DEFA14A reportApr 29, 2026
- 8-K reportApr 9, 2026
- CLUSTER reportMar 10, 2026
- CLUSTER reportMar 5, 2026
- CLUSTER reportFeb 25, 2026